These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 19414257)

  • 1. Discovery of a novel HCV helicase inhibitor by a de novo drug design approach.
    Kandil S; Biondaro S; Vlachakis D; Cummins AC; Coluccia A; Berry C; Leyssen P; Neyts J; Brancale A
    Bioorg Med Chem Lett; 2009 Jun; 19(11):2935-7. PubMed ID: 19414257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific targeting of hepatitis C virus NS3 RNA helicase. Discovery of the potent and selective competitive nucleotide-mimicking inhibitor QU663.
    Maga G; Gemma S; Fattorusso C; Locatelli GA; Butini S; Persico M; Kukreja G; Romano MP; Chiasserini L; Savini L; Novellino E; Nacci V; Spadari S; Campiani G
    Biochemistry; 2005 Jul; 44(28):9637-44. PubMed ID: 16008349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Helicase, a target for novel inhibitors of hepatitis C virus.
    Yao N; Weber PC
    Antivir Ther; 1998; 3(Suppl 3):93-7. PubMed ID: 10726059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-time monitoring of RNA helicase activity using fluorescence resonance energy transfer in vitro.
    Tani H; Fujita O; Furuta A; Matsuda Y; Miyata R; Akimitsu N; Tanaka J; Tsuneda S; Sekiguchi Y; Noda N
    Biochem Biophys Res Commun; 2010 Feb; 393(1):131-6. PubMed ID: 20117090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Designing and analysis of a potent bi-functional aptamers that inhibit protease and helicase activities of HCV NS3.
    Umehara T; Fukuda K; Nishikawa F; Sekiya S; Kohara M; Hasegawa T; Nishikawa S
    Nucleic Acids Symp Ser (Oxf); 2004; (48):195-6. PubMed ID: 17150545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated strategies for identifying leads that target the NS3 helicase of the hepatitis C virus.
    LaPlante SR; Padyana AK; Abeywardane A; Bonneau P; Cartier M; Coulombe R; Jakalian A; Wildeson-Jones J; Li X; Liang S; McKercher G; White P; Zhang Q; Taylor SJ
    J Med Chem; 2014 Mar; 57(5):2074-90. PubMed ID: 24467709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis C NS3-4A protease using structure-based drug design.
    Venkatraman S; Njoroge FG; Girijavallabhan VM; Madison VS; Yao NH; Prongay AJ; Butkiewicz N; Pichardo J
    J Med Chem; 2005 Aug; 48(16):5088-91. PubMed ID: 16078825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies on the anti-hepatitis C virus activity of newly synthesized tropolone derivatives: identification of NS3 helicase inhibitors that specifically inhibit subgenomic HCV replication.
    Najda-Bernatowicz A; Krawczyk M; Stankiewicz-Drogoń A; Bretner M; Boguszewska-Chachulska AM
    Bioorg Med Chem; 2010 Jul; 18(14):5129-36. PubMed ID: 20579888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational Drug Discovery of HCV Helicase Inhibitor: Improved Docking Accuracy with Multiple Seeding in AutoDock Vina and In Situ Minimization.
    Lim SK; Othman R; Yusof R; Heh CH
    Curr Comput Aided Drug Des; 2017; 13(2):160-169. PubMed ID: 27903217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-throughput screening assay of hepatitis C virus helicase inhibitors using fluorescence-quenching phenomenon.
    Tani H; Akimitsu N; Fujita O; Matsuda Y; Miyata R; Tsuneda S; Igarashi M; Sekiguchi Y; Noda N
    Biochem Biophys Res Commun; 2009 Feb; 379(4):1054-9. PubMed ID: 19150342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro selection of RNA aptamers against the HCV NS3 helicase domain.
    Nishikawa F; Funaji K; Fukuda K; Nishikawa S
    Oligonucleotides; 2004; 14(2):114-29. PubMed ID: 15294075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational design of dual-functional aptamers that inhibit the protease and helicase activities of HCV NS3.
    Umehara T; Fukuda K; Nishikawa F; Kohara M; Hasegawa T; Nishikawa S
    J Biochem; 2005 Mar; 137(3):339-47. PubMed ID: 15809335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macrocyclic inhibitors of HCV NS3 protease.
    Venkatraman S; Njoroge FG
    Expert Opin Ther Pat; 2009 Sep; 19(9):1277-303. PubMed ID: 19563268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent aza-peptide derived inhibitors of HCV NS3 protease.
    Venkatraman S; Wu W; Shih NY; George Njoroge F
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4760-3. PubMed ID: 19596195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quinolones as HCV NS5B polymerase inhibitors.
    Kumar DV; Rai R; Brameld KA; Somoza JR; Rajagopalan R; Janc JW; Xia YM; Ton TL; Shaghafi MB; Hu H; Lehoux I; To N; Young WB; Green MJ
    Bioorg Med Chem Lett; 2011 Jan; 21(1):82-7. PubMed ID: 21145235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel phosphonate derivatives as hepatitis C virus NS3 protease inhibitors.
    Sheng XC; Pyun HJ; Chaudhary K; Wang J; Doerffler E; Fleury M; McMurtrie D; Chen X; Delaney WE; Kim CU
    Bioorg Med Chem Lett; 2009 Jul; 19(13):3453-7. PubMed ID: 19477126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based discovery of triphenylmethane derivatives as inhibitors of hepatitis C virus helicase.
    Chen CS; Chiou CT; Chen GS; Chen SC; Hu CY; Chi WK; Chu YD; Hwang LH; Chen PJ; Chen DS; Liaw SH; Chern JW
    J Med Chem; 2009 May; 52(9):2716-23. PubMed ID: 19419203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of novel P3 sulfonamide-capped inhibitors of HCV NS3 protease. Inhibitors with improved cellular potencies.
    Venkatraman S; Blackman M; Wu W; Nair L; Arasappan A; Padilla A; Bogen S; Bennett F; Chen K; Pichardo J; Tong X; Prongay A; Cheng KC; Girijavallabhan V; George Njoroge F
    Bioorg Med Chem; 2009 Jul; 17(13):4486-95. PubMed ID: 19481946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure and function of hepatitis C virus NS3 helicase.
    Kwong AD; Kim JL; Lin C
    Curr Top Microbiol Immunol; 2000; 242():171-96. PubMed ID: 10592661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of a novel series of non-nucleoside thumb pocket 2 HCV NS5B polymerase inhibitors.
    Stammers TA; Coulombe R; Rancourt J; Thavonekham B; Fazal G; Goulet S; Jakalian A; Wernic D; Tsantrizos Y; Poupart MA; Bös M; McKercher G; Thauvette L; Kukolj G; Beaulieu PL
    Bioorg Med Chem Lett; 2013 May; 23(9):2585-9. PubMed ID: 23545108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.